Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Heeg

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|November 2, 2019
The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluationsSamron Brhane Gebregergish, Mahmoud Hashim, Bart Heeg, et al.
Journal of Medical Economics|January 7, 2020
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of <i>RAS</i> wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) studySebastian Stintzing, Ilse van Oostrum, Chris P Pescott, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013Mata Charokopou, Istvan M Majer, Johan de Raad, et al.
Research Synthesis Methods|October 25, 2022
Network meta-interpolation: Effect modification adjustment in network meta-analysis using subgroup analysesOfir Harari, Mohsen Soltanifar, Joseph C Cappelleri, et al.
Future Oncology (London, England)|April 16, 2021
Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patientsBogdan Muresan, Carla Mamolo, Joseph C Cappelleri, et al.
Journal of Comparative Effectiveness Research|January 18, 2023
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturityBart Heeg, Andre Verhoek, Gabriel Tremblay, et al.
Clinical Lung Cancer|July 14, 2023
MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and OutcomesJulien Mazieres, Helene Vioix, Boris M Pfeiffer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021
Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology DrugsIlse van Oostrum, Mario Ouwens, Antonio Remiro-Azócar, et al.
Future Oncology (London, England)|February 24, 2022
Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature reviewT Alexander Russell-Smith, Laura Gurskyte, Bogdan Muresan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
The cost-effectiveness of atypicals in the UKBart Heeg, Erik Buskens, Marc Botteman, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Expert Review of Pharmacoeconomics & Outcomes Research|November 2, 2019
The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluationsSamron Brhane Gebregergish, Mahmoud Hashim, Bart Heeg, et al.
Journal of Medical Economics|January 7, 2020
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of <i>RAS</i> wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) studySebastian Stintzing, Ilse van Oostrum, Chris P Pescott, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013Mata Charokopou, Istvan M Majer, Johan de Raad, et al.
Research Synthesis Methods|October 25, 2022
Network meta-interpolation: Effect modification adjustment in network meta-analysis using subgroup analysesOfir Harari, Mohsen Soltanifar, Joseph C Cappelleri, et al.
Future Oncology (London, England)|April 16, 2021
Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patientsBogdan Muresan, Carla Mamolo, Joseph C Cappelleri, et al.
Journal of Comparative Effectiveness Research|January 18, 2023
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturityBart Heeg, Andre Verhoek, Gabriel Tremblay, et al.
Clinical Lung Cancer|July 14, 2023
MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and OutcomesJulien Mazieres, Helene Vioix, Boris M Pfeiffer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021
Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology DrugsIlse van Oostrum, Mario Ouwens, Antonio Remiro-Azócar, et al.
Future Oncology (London, England)|February 24, 2022
Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature reviewT Alexander Russell-Smith, Laura Gurskyte, Bogdan Muresan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
The cost-effectiveness of atypicals in the UKBart Heeg, Erik Buskens, Marc Botteman, et al.
Pageof 5